Organization (Hospital)
National Jewish Health
ClinicalTrials.gov lists National Jewish Health as lead sponsor of 109 trials. It has 19 active development programs and 24 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 2 registered with a 2026 start date. The dashed outline is the pace from the 2 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 2.8 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers National Jewish Health: 109 lead-sponsored trials and 1 legal-entity registration.
Disease areas (81)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Cystic Fibrosis | 25 |
| Asthma | 24 |
| Pulmonary Disease, Chronic Obstructive | 19 |
| Lung Diseases, Interstitial | 18 |
| Dermatitis, Atopic | 10 |
Showing 5 of 81 disease areas.
Trials by start year as sponsor or collaborator (26)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2025 | 4 |
| 2024 | 3 |
| 2023 | 3 |
| 2022 | 2 |
| 2021 | 8 |
| 2020 | 13 |
| 2019 | 14 |
| 2018 | 13 |
| 2017 | 11 |
Showing 10 of 26 years.
Recruitment duration, a model prediction: 3 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (19)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Sildenafil 40mg oral capsule | Cystic Fibrosis | Phase 2/3 | 1 |
| BENRALIZUMAB | Asthma | Phase 2 | 1 |
| Reslizumab | Asthma | Phase 2 | 1 |
| SILDENAFIL | Cystic Fibrosis | Phase 2 | 3 |
| Saracatinab | Idiopathic Pulmonary Fibrosis | Phase 1/2 | 1 |
Showing 5 of 19 active programs.
Approved assets (24)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Budesonide | 1 |
| Omalizumab Injection | 1 |
| Budesonide / Formoterol | 1 |
| Ipratropium/albuterol | 1 |
| Tobramycin | 1 |
Showing 5 of 24 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 47% hit target (n=32) | 39% on time (n=38) |
Journals published in (132)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| American journal of respiratory and critical care medicine | 37 |
| Chest | 20 |
| Annals of the American Thoracic Society | 16 |
| Chronic obstructive pulmonary diseases (Miami, Fla.) | 11 |
| Respiratory research | 11 |
Showing 5 of 132 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 135 | 23 | 2025-11-25 |
Financing and grant events (272)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2026-01-14 | NIH grant | 409,658 | Reporter |
| 2025-09-30 | NIH grant | 10,214,399 | Reporter |
| 2025-09-04 | NIH grant | 7,849,476 | Reporter |
| 2025-08-28 | NIH grant | 1,508,830 | Reporter |
| 2025-08-27 | NIH grant | 511,805 | Reporter |
Showing 5 of 272 events.
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| NAI | 3 |
Organization relationships (58)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Government of the United States of America | Co sponsors trial with | 3 |
| University of Colorado System | Co sponsors trial with | 2 |
| University of California System | Co sponsors trial with | 2 |
| University of Pittsburgh | Co sponsors trial with | 2 |
| Pulmonary Fibrosis Foundation | Co sponsors trial with | 2 |
Showing 5 of 58 relationships.
Latest dated events (557)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-08-12 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-02-03 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-01-14 | NIH grant | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2025-12 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-11-25 | Patent granted | Granted US patents (PatentsView / USPTO) |
Showing 5 of 557 events.
CLIA clinical laboratory certificates (3)
Shown in this order: active first, then certificate type.
| Lab | Certificate | Status |
|---|---|---|
| NATIONAL JEWISH HEALTH | Certificate of accreditation | Active |
| NATIONAL JEWISH HEALTH | Certificate of compliance | Active |
| NATIONAL JEWISH HEALTH | Certificate of waiver | Active |
Biomarker capability evidence (197)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| APEX1 | Trial sponsor | Named in trial inclusion criteria |
| CCDC88A | Trial sponsor | Named in trial inclusion criteria |
| CD4 | Trial sponsor | Named in trial inclusion criteria |
| CFTR | Trial sponsor | Named in trial inclusion criteria |
| CFTR | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 197 evidence rows.
Biomarkers this organization publishes on (45)
Shown in this order: most publications first.
Showing 5 of 45 biomarkers.
On Scientist.com
National Jewish Health is listed as a research supplier in the Scientist.com network.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sec-reported annual financials, fda warning letters, fda untitled letters, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, and workforce and board diversity, as filed.
Work with National Jewish Health Mouse Genetics on Scientist.com
For prices, more details, or to contact National Jewish Health Mouse Genetics, visit Scientist.com.
Sign in to Scientist.com to open this supplier in your organization's marketplace.